IDO and outcomes in ovarian cancer

Gynecol Oncol. 2009 Nov;115(2):179-80. doi: 10.1016/j.ygyno.2009.09.017.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • CD8-Positive T-Lymphocytes / immunology
  • Drug Synergism
  • Female
  • Humans
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / antagonists & inhibitors
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / biosynthesis*
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / immunology
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / enzymology*
  • Ovarian Neoplasms / immunology
  • Paclitaxel / administration & dosage
  • Paclitaxel / pharmacology
  • Prognosis
  • Tryptophan / administration & dosage
  • Tryptophan / analogs & derivatives
  • Tryptophan / pharmacology

Substances

  • Indoleamine-Pyrrole 2,3,-Dioxygenase
  • Tryptophan
  • Paclitaxel
  • 1-methyltryptophan